Venus Remedies jumps over 8% on securing marketing authorisations for Docetaxel
The company has secured marketing authorisations for three variants of Docetaxel in Israel and Cytarabine 100MG in Colombia.
On Thursday, Venus Remedies shares jumped 8.41% to trade at Rs 407.60, from its previous closing of Rs 375.95 on the BSE.
Venus Remedies has secured marketing authorizations for three variants of Docetaxel in Israel and Cytarabine 100MG in Colombia. The approved Docetaxel variants (160MG/8ML, 80MG/4ML, 20MG/1ML) and Cytarabine further solidify their commitment to advancing healthcare solutions globally.
Earlier, the company had unveiled a significant transformation of its consumer healthcare division, R3SET. This strategic pivot marks R3SET’s foray into the wellness arena, coupled with the expansion of its pain management portfolio, showcasing the company’s holistic approach to wellness solutions.
Venus Remedies Ltd is an Indian pharmaceutical company with a presence in domestic and international markets. It is primarily engaged in the business of pharmaceutical product manufacturing. The company is one of the few players in the pharmaceutical sector to launch world global injectable manufacturers. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America arid the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices.
Today, the shares of Venus Remedies closed at Rs 399.40, up by 6.24% from its previous closing. The stock opened at Rs 375.95 and has touched a high and low of Rs 407.60 and Rs 371.30, respectively. The BSE group ‘B’ stock of face value of Rs 10 has a 52-week high and low of Rs 419.05 and Rs 145, respectively. Last one week high and low of the scrip stood at Rs 407.60 and Rs 371.40, respectively. The current market cap of the company is Rs 537.35 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.03% and 57.21% respectively.
Disclaimer: This post has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.